The war on cancer—a status report
Editor’s Note: This story, first published in 2004, has been updated.
In 2004, FORTUNE magazine created a stir in the research community with a cover story entitled “Why we’re losing the war on cancer (and how to win it).”
The story’s author, Clifton Leaf, one of magazine’s executive editors and a cancer survivor, described "a dysfunctional 'cancer culture' ... that pushes ... physicians and scientists toward the goal of tiniest improvements in treatment rather than genuine breakthroughs."
Scientists interviewed for this issue of Lens disputed the “dysfunctional” label, but they said they could make faster progress if there were greater incentives for collaboration among researchers, clinicians and drug companies.
“Patients are going to benefit the most from combinational approaches,” yet current patent and regulatory constraints make it difficult to test new drugs in combination, notes Lisa Coussens, Ph.D., a cancer researcher at the University of California, San Francisco. “You have to test them as single agents and if they don’t demonstrate efficacy, they’re not going to go any further.”
Junior faculty also are discouraged from collaborating with each other because they have to demonstrate independence in order to be promoted and win research grants, Coussens says. Yet that’s exactly what’s needed to make progress, maintains Ernest Hawk, M.D., MPH, vice president for cancer prevention and population sciences at the University of Texas M.D. Anderson Cancer Center in Houston.
“I’m not talking revolution here, but it’s something the whole culture needs to take a look at,” says Hawk, who formerly lead gastrointestinal research in the National Cancer Institute’s Division of Cancer Prevention. “Getting researchers working together rather than quite so independently will reduce redundancy and perhaps maximize the effort we’re putting forward.”